重组血管紧张素转换酶2对高血压小鼠肾脏Nephrin信号及结构损伤的影响

Effects of recombinant angiotensin-converting enzyme 2on renal Nephrin signaling and structural injury in hypertensive mice

  • 摘要: 目的探讨高血压状态下肾脏组织足细胞蛋白Nephrin信号改变以及重组血管紧张素转换酶2(ACE2)干预治疗对该信号和肾脏超微结构改变的影响。方法采用10~11周龄C57/B6小鼠,随机分成3组:正常对照组(n=8);高血压+安慰剂组(n=6);高血压+重组ACE2干预组(n=6)。高血压+安慰剂组和高血压+重组ACE2干预组小鼠每天经微泵给予1.5mg/kg血管紧张素Ⅱ(AngⅡ)制备高血压模型,然后每天分别经腹腔注射给予安慰剂或重组ACE2 2mg/kg治疗,为期2周。用尾套法测定小鼠血压水平。采用Western-blot及硫代巴比妥酸比色法检测小鼠肾脏组织中Nephrin表达和丙二醛含量。用透射电镜技术观测小鼠肾脏超微结构改变。结果与正常对照组相比,高血压+安慰剂组小鼠血压水平明显升高(156.2±9.8)比(100.8±9.9)mm Hg,P<0.01,肾脏组织中Nephrin蛋白表达下调,丙二醛含量增加Nephrin相对表达:0.48±0.06比1.00±0.08;丙二醛(159.6±12.1)比(55.2±9.0)nmol/g,均P<0.01,与高血压+安慰剂组相比,高血压+重组ACE2组小鼠血压明显下降(134.8±8.3)比(156.2±9.8)mm Hg,P<0.05,肾脏组织Nephrin表达增加,丙二醛含量下降Nephrin:0.71±0.07比0.48±0.06;丙二醛:(98.5±11.5)比(159.6±12.1)nmol/g,均P<0.05。另外,重组ACE2干预明显改善高血压小鼠肾脏功能,并减轻肾脏超微结构损伤,表现为肾小管空泡线粒体结构减少,肾小球基底膜增厚与足突细胞融合现象得到改善。结论高血压状态下存在肾脏组织中Nephrin信号下调,伴有氧化应激增强和结构损伤明显,而重组ACE2治疗通过改善高血压小鼠肾脏Nephrin表达水平,可促使肾脏氧化应激水平降低与结构损伤减轻,提示ACE2对高血压具有一定的肾脏保护功效。

     

    Abstract: Objective To investigate the alteration of renal podocyte Nephrin signaling and ultrastructural injury in hypertension state and the effects of recombinant human angiotensin-converting enzyme 2(rhACE2)on these alterations. Methods The 10-or 11-week C57/B6 mice were randomized to three groups,including the normal control group(n=8),the hypertension+placebo group(n=6)and the hypertension+rhACE2treatment group(n=6).Hypertensive model was established by infusion of angiotensin Ⅱ(Ang Ⅱ)daily with the dose of 1.5mg/kg,and the hypertensive mice were then treated with rhACE2(2mg/kg per day,intraperitoneal)or placebo for 2weeks.The systolic blood pressure(SBP)of mice was measured by the tail-cuff method. Nephrin protein and malonyldialdehyde(MDA)concentrations in mouse kidneys were determined with Western blot and thiobarbituric acid(TBA)reactive substances methods,respectively. In addition,renal ultrastructure was observed via transmission electron microscope. Results Compared with control group,SBP levels were obviously elevated in the Ang Ⅱ-induced hypertensive mice(156.2±9.8)vs(100.8±9.9)mm Hg,P<0.01,associated with reduced Nephrin protein levels and enhanced MDA contentNephrin:0.48±0.06 vs 1.00±0.08 and MDA(159.6±12.1)vs(55.2±9.0)nmol/g,P<0.01,respectively. Compared with hypertension+placebo group,treatment with rhACE2 significantly decreased SBP levels(134.8±8.3)vs(156.2±9.8)mm Hg,P<0.05,and promoted renal Nephrin levels in hypertensive mice,along with a marked reduction in MDA contentsNephrin:0.71±0.07 vs 0.48±0.06 and MDA(98.5±11.5)vs(159.6±12.1)nmol/g,P<0.05,respectively. Finally,treatment with rhACE2 strikingly attenuated renal ultrastructure injury in hypertensive mice,characterized with the decrease of vacuolizated mitochondria in renal tubular,and improvement of the thickening glomerular capillary basement membrane and foot process effacement in podocytes. Conclusions There are diminished Nephrin signaling,augmented oxidative stress and ultrastructure injury in kidneys of hypertensive mice. Treatment with rhACE2 can improve renal expression of Nephrin,which further contribute to attenuation of oxidative stress and renal ultrastructure injury in hypertensive mice,implying that ACE2 has a potential renoprotective effect in hypertension.

     

/

返回文章
返回